Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136585> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4324136585 endingPage "694" @default.
- W4324136585 startingPage "694" @default.
- W4324136585 abstract "694 Background: The treatment landscape of localized renal cell carcinoma (RCC) is rapidly evolving. Recent trials have demonstrated contrasting efficacy with adjuvant immunotherapy. Therefore, we sought to assess the mixed treatment comparisons among different adjuvant treatment options using updated data from trials and quantified the absolute effect with these treatments stratified by risk categories. Methods: This living network meta-analysis was conducted using the living interactive evidence (LIvE) synthesis framework. We used stratified baseline risks of disease progression from observational data and at 5, 10, 15 years from the Leibovich risk stratification system (based on risk scores ranging from 0 to ≥15). Corresponding intervention risks were then approximated using relative effect estimates (from NMA) and baseline risks. The difference between CIRs and baseline risks were calculated to present absolute risk differences in each risk category. Results: This NMA included eight RCTs with 8480 participants and seven unique treatment options. Pembrolizumab (pembro; rank 1) was associated with improved disease-free survival (DFS) when compared to atezolizumab (atezo; rank 6; hazard ratio: 0.68; 0.49;0.93), and nivolumab-ipilimumab (nivoipi; rank 5; 0.68; 0.48-0.97). However, no statistically significant difference was observed between pembro and atezo for overall survival (0.53; 0.28-1.01). Survival data for nivoIpi was not reported. No new statistically significant differences were observed since last update. The absolute benefit of atezo and nivoipi was minimal with higher T and N patients (Table). The results were similar with increasing Leibovich risk scores. Conclusions: Current evidence favors the use of a risk adapted approach when offering adjuvant immunotherapy. Adjuvant pembrolizumab remains a preferred treatment in patients with RCC who underwent nephrectomy. [Table: see text]" @default.
- W4324136585 created "2023-03-15" @default.
- W4324136585 creator A5005768868 @default.
- W4324136585 creator A5013043483 @default.
- W4324136585 creator A5018306647 @default.
- W4324136585 creator A5030233600 @default.
- W4324136585 creator A5049071296 @default.
- W4324136585 creator A5049546835 @default.
- W4324136585 creator A5058650905 @default.
- W4324136585 creator A5061753488 @default.
- W4324136585 creator A5063368856 @default.
- W4324136585 creator A5065226003 @default.
- W4324136585 creator A5067550666 @default.
- W4324136585 creator A5068639858 @default.
- W4324136585 creator A5068844570 @default.
- W4324136585 creator A5074582149 @default.
- W4324136585 date "2023-02-20" @default.
- W4324136585 modified "2023-09-23" @default.
- W4324136585 title "Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA)." @default.
- W4324136585 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.694" @default.
- W4324136585 hasPublicationYear "2023" @default.
- W4324136585 type Work @default.
- W4324136585 citedByCount "1" @default.
- W4324136585 countsByYear W43241365852023 @default.
- W4324136585 crossrefType "journal-article" @default.
- W4324136585 hasAuthorship W4324136585A5005768868 @default.
- W4324136585 hasAuthorship W4324136585A5013043483 @default.
- W4324136585 hasAuthorship W4324136585A5018306647 @default.
- W4324136585 hasAuthorship W4324136585A5030233600 @default.
- W4324136585 hasAuthorship W4324136585A5049071296 @default.
- W4324136585 hasAuthorship W4324136585A5049546835 @default.
- W4324136585 hasAuthorship W4324136585A5058650905 @default.
- W4324136585 hasAuthorship W4324136585A5061753488 @default.
- W4324136585 hasAuthorship W4324136585A5063368856 @default.
- W4324136585 hasAuthorship W4324136585A5065226003 @default.
- W4324136585 hasAuthorship W4324136585A5067550666 @default.
- W4324136585 hasAuthorship W4324136585A5068639858 @default.
- W4324136585 hasAuthorship W4324136585A5068844570 @default.
- W4324136585 hasAuthorship W4324136585A5074582149 @default.
- W4324136585 hasConcept C121608353 @default.
- W4324136585 hasConcept C126322002 @default.
- W4324136585 hasConcept C143998085 @default.
- W4324136585 hasConcept C207103383 @default.
- W4324136585 hasConcept C2775949291 @default.
- W4324136585 hasConcept C2777472916 @default.
- W4324136585 hasConcept C2777701055 @default.
- W4324136585 hasConcept C2777863537 @default.
- W4324136585 hasConcept C2780030458 @default.
- W4324136585 hasConcept C2780057760 @default.
- W4324136585 hasConcept C2781433595 @default.
- W4324136585 hasConcept C44249647 @default.
- W4324136585 hasConcept C71924100 @default.
- W4324136585 hasConcept C95190672 @default.
- W4324136585 hasConceptScore W4324136585C121608353 @default.
- W4324136585 hasConceptScore W4324136585C126322002 @default.
- W4324136585 hasConceptScore W4324136585C143998085 @default.
- W4324136585 hasConceptScore W4324136585C207103383 @default.
- W4324136585 hasConceptScore W4324136585C2775949291 @default.
- W4324136585 hasConceptScore W4324136585C2777472916 @default.
- W4324136585 hasConceptScore W4324136585C2777701055 @default.
- W4324136585 hasConceptScore W4324136585C2777863537 @default.
- W4324136585 hasConceptScore W4324136585C2780030458 @default.
- W4324136585 hasConceptScore W4324136585C2780057760 @default.
- W4324136585 hasConceptScore W4324136585C2781433595 @default.
- W4324136585 hasConceptScore W4324136585C44249647 @default.
- W4324136585 hasConceptScore W4324136585C71924100 @default.
- W4324136585 hasConceptScore W4324136585C95190672 @default.
- W4324136585 hasIssue "6_suppl" @default.
- W4324136585 hasLocation W43241365851 @default.
- W4324136585 hasOpenAccess W4324136585 @default.
- W4324136585 hasPrimaryLocation W43241365851 @default.
- W4324136585 hasRelatedWork W2493521471 @default.
- W4324136585 hasRelatedWork W2800311363 @default.
- W4324136585 hasRelatedWork W2968490685 @default.
- W4324136585 hasRelatedWork W2969738919 @default.
- W4324136585 hasRelatedWork W2981883049 @default.
- W4324136585 hasRelatedWork W3104828024 @default.
- W4324136585 hasRelatedWork W3170189973 @default.
- W4324136585 hasRelatedWork W3215044659 @default.
- W4324136585 hasRelatedWork W3216520672 @default.
- W4324136585 hasRelatedWork W4318473990 @default.
- W4324136585 hasVolume "41" @default.
- W4324136585 isParatext "false" @default.
- W4324136585 isRetracted "false" @default.
- W4324136585 workType "article" @default.